Ultragenyx Pharmaceutical(RARE) - 2024 Q1 - Earnings Call Transcript

Company Participants Conference Call Participants Operator Joshua Higa Emil Kakkis The support of Peter Marks and the FDA in recognizing this biomarker as a surrogate endpoint to support accelerated approval would be a profound benefit for the MPS communities and companies working on these diseases and really to all companies working on gene therapies or other type precision medicines. Ultragenyx Pharmaceutical, Inc. (NASDAQ:RARE) Q1 2024 Earnings Conference Call May 2, 2024 5:00 PM ET Joshua Higa - Vice Pr ...